Area of research
Genetics · Molecular Biology
Research interest
Research interests include Glioma Diagnosis and Treatment, Cancer Research and Treatments, Cancer, Hypoxia, and Metabolism, and Epigenetics and DNA Methylation.
Targeting Pediatric Glioblastomas by Combining OLIG2 Inhibitor CT-179 with Fractionated Radiation in a Panel of Patient-Derived Orthotopic Xenograft Mouse Models.
Nondestructive Quality Detection of Characteristic Fruits Based on Vis/NIR Spectroscopy: Principles, Systems, and Applications
Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations
Fractionated radiation therapy alters energy metabolism and induces cellular quiescence exit in patient-derived orthotopic xenograft models of high-grade glioma
CD57 defines a novel cancer stem cell that drive invasion of diffuse pediatric-type high grade gliomas.
Silencing GMPPB Inhibits the Proliferation and Invasion of GBM via Hippo/MMP3 Pathways
Targeting GBM with an Oncolytic Picornavirus SVV-001 alone and in combination with fractionated Radiation in a Novel Panel of Orthotopic PDX models.
Scalp ripple rates for rapid epilepsy differentiation and seizure activity assessment: Applicability and influential factors
Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Table from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Data from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Data from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Data from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Data from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models
Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAF<sup>V600E</sup></i> Brain Tumor Models